Reported Earlier, Amgen Says Repatha Cut Death Risk By 20% In High-Risk Heart Patients
Amgen (NASDAQ:AMGN) today announced new findings showing Repatha® (evolocumab) reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other low-density lipoprotein
Amgen's heart medicine Repatha helped people stay healthier by lowering their death risk by 20%. When a company shows its medicine really works, people often feel more confident about buying its stock.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.